JPWO2020064744A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020064744A5 JPWO2020064744A5 JP2021516368A JP2021516368A JPWO2020064744A5 JP WO2020064744 A5 JPWO2020064744 A5 JP WO2020064744A5 JP 2021516368 A JP2021516368 A JP 2021516368A JP 2021516368 A JP2021516368 A JP 2021516368A JP WO2020064744 A5 JPWO2020064744 A5 JP WO2020064744A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- composition
- cancer
- polynucleotide
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims description 24
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 24
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 15
- 239000002671 adjuvant Substances 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 108091033319 polynucleotide Proteins 0.000 claims description 9
- 102000040430 polynucleotide Human genes 0.000 claims description 9
- 239000002157 polynucleotide Substances 0.000 claims description 9
- 201000011510 cancer Diseases 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 4
- 102100021723 Arginase-1 Human genes 0.000 claims description 4
- 101710129000 Arginase-1 Proteins 0.000 claims description 4
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 claims description 4
- 238000006467 substitution reaction Methods 0.000 claims description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 2
- 102000004452 Arginase Human genes 0.000 claims description 2
- 108700024123 Arginases Proteins 0.000 claims description 2
- 108020000946 Bacterial DNA Proteins 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 2
- 150000001408 amides Chemical class 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 239000003599 detergent Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 230000005847 immunogenicity Effects 0.000 claims description 2
- 230000001506 immunosuppresive effect Effects 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 238000011275 oncology therapy Methods 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 230000002335 preservative effect Effects 0.000 claims description 2
- 230000004936 stimulating effect Effects 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- RHKWIGHJGOEUSM-UHFFFAOYSA-N 3h-imidazo[4,5-h]quinoline Chemical class C1=CN=C2C(N=CN3)=C3C=CC2=C1 RHKWIGHJGOEUSM-UHFFFAOYSA-N 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 238000011260 co-administration Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1815549.9A GB201815549D0 (en) | 2018-09-24 | 2018-09-24 | Arginase1 polypeptides |
| GB1815549.9 | 2018-09-24 | ||
| PCT/EP2019/075731 WO2020064744A1 (en) | 2018-09-24 | 2019-09-24 | Arginase1 polypeptides |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022501046A JP2022501046A (ja) | 2022-01-06 |
| JP2022501046A5 JP2022501046A5 (https=) | 2022-08-30 |
| JPWO2020064744A5 true JPWO2020064744A5 (https=) | 2022-08-30 |
| JP7624388B2 JP7624388B2 (ja) | 2025-01-30 |
Family
ID=64024184
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021516368A Active JP7624388B2 (ja) | 2018-09-24 | 2019-09-24 | アルギナーゼ１ポリペプチド |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US12194081B2 (https=) |
| EP (1) | EP3856899A1 (https=) |
| JP (1) | JP7624388B2 (https=) |
| KR (1) | KR20210091696A (https=) |
| CN (1) | CN112771159B (https=) |
| AU (1) | AU2019350356B9 (https=) |
| CA (1) | CA3113004A1 (https=) |
| GB (1) | GB201815549D0 (https=) |
| IL (1) | IL281762A (https=) |
| MX (1) | MX2021003441A (https=) |
| SG (1) | SG11202102378WA (https=) |
| WO (1) | WO2020064744A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201818576D0 (en) | 2018-11-14 | 2018-12-26 | Io Biotech Aps | Arginase 2 polypeptides |
| WO2023161350A1 (en) | 2022-02-24 | 2023-08-31 | Io Biotech Aps | Nucleotide delivery of cancer therapy |
| JP2025508840A (ja) | 2022-02-24 | 2025-04-10 | アイオー バイオテック エーピーエス | アルギナーゼ２ワクチン |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US58767A (en) | 1866-10-16 | John brougjbton | ||
| US5554372A (en) | 1986-09-22 | 1996-09-10 | Emory University | Methods and vaccines comprising surface-active copolymers |
| US5780286A (en) | 1996-03-14 | 1998-07-14 | Smithkline Beecham Corporation | Arginase II |
| US20110111424A1 (en) | 2001-06-21 | 2011-05-12 | Cell Signaling Technology, Inc. | Analysis of ubiquitinated polypeptides |
| US20030228583A1 (en) | 2001-10-31 | 2003-12-11 | Amacher David E. | Biomarkers of liver response |
| CA2586048C (en) | 2004-10-29 | 2014-03-11 | Gregg A. Howe | Protection against herbivores |
| PT3778885T (pt) | 2008-10-31 | 2023-05-31 | Aerase Inc | Composições de arginases humanas modificadas e métodos para o tratamento do cancro |
| CN101781369A (zh) * | 2009-01-20 | 2010-07-21 | 江苏先声药物研究有限公司 | 一种重组人精氨酸酶融合蛋白及其应用 |
| ES2897635T3 (es) | 2014-04-29 | 2022-03-02 | Bio Cancer Treat International Ltd | Métodos y composiciones para modular el sistema inmunológico con la arginasa I |
| GB201501017D0 (en) | 2014-12-23 | 2015-03-04 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers |
| JP7211938B2 (ja) * | 2016-10-07 | 2023-01-24 | アイオー バイオテック エーピーエス | 免疫原性アルギナーゼペプチド |
-
2018
- 2018-09-24 GB GBGB1815549.9A patent/GB201815549D0/en not_active Ceased
-
2019
- 2019-09-24 WO PCT/EP2019/075731 patent/WO2020064744A1/en not_active Ceased
- 2019-09-24 CN CN201980062504.7A patent/CN112771159B/zh active Active
- 2019-09-24 JP JP2021516368A patent/JP7624388B2/ja active Active
- 2019-09-24 US US17/278,838 patent/US12194081B2/en active Active
- 2019-09-24 SG SG11202102378WA patent/SG11202102378WA/en unknown
- 2019-09-24 AU AU2019350356A patent/AU2019350356B9/en active Active
- 2019-09-24 CA CA3113004A patent/CA3113004A1/en active Pending
- 2019-09-24 EP EP19779801.0A patent/EP3856899A1/en active Pending
- 2019-09-24 MX MX2021003441A patent/MX2021003441A/es unknown
- 2019-09-24 KR KR1020217010964A patent/KR20210091696A/ko active Pending
-
2021
- 2021-03-24 IL IL281762A patent/IL281762A/en unknown
-
2024
- 2024-11-01 US US18/935,162 patent/US20250205318A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2000006602A1 (ja) | 癌抑制遺伝子ｗｔ１の産物に基づく癌抗原 | |
| PT1659178E (pt) | Processo para a purificação ou produção de uma proteína mage | |
| RU2007119319A (ru) | Наборы антигенов полипептида, угнетающего секрецию желудка (gip), и их применение | |
| JP2022507373A5 (https=) | ||
| JP2008530975A5 (https=) | ||
| JP2022501046A5 (https=) | ||
| CN1106846C (zh) | 抗癌症剂 | |
| KR102073144B1 (ko) | 올리고펩티드를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물 | |
| EP2766384B1 (en) | Toll-like receptor 4 (tlr-4) agonist peptides for modulating tlr-4 mediated immune response | |
| JP2018509423A5 (https=) | ||
| JP5036546B2 (ja) | 胸腺特異的タンパク質 | |
| JPWO2020064744A5 (https=) | ||
| JPWO2020099582A5 (https=) | ||
| US20080026995A1 (en) | Therapeutic vaccine targeted against p-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers | |
| US8207141B2 (en) | Plasmids coding for p185neu protein sequence variants and therapeutic uses thereof | |
| JPWO2020245264A5 (https=) | ||
| DE10006033A1 (de) | Immunisierung eines Individuums gegen Carcinome und ihre Vorstufen | |
| CN116390768A (zh) | 具有抗癌活性的免疫调节蛋白-siRNA复合物 | |
| KR20250057646A (ko) | Kras 면역원성 펩타이드 | |
| JPWO2022215032A5 (https=) | ||
| US20030082201A1 (en) | Multivalent synthetic vaccine for cancer | |
| CN115335075A (zh) | 治疗和预防乙型肝炎和丁型肝炎的组合物和方法 | |
| WO2001042460A1 (fr) | Polynucleotides, polypeptides, remedes contre le cancer et vaccins | |
| CN1562375A (zh) | 具有放射保护和抗肿瘤作用的减毒沙门氏菌药物组合物 |